Bombas de Efluxo em Pseudomonas Aeruginosa. Importância Clínica na Terapêutica

As infecções severas causadas por Pseudomonas Aeruginosa têm assumido na última década um papel de destaque, dado tratar-se de um microrganismo de difícil erradicação e com elevada resistência intrínseca e adquirida. Em P. aeruginosa foram caracterizados sete sistemas de bombas de efluxo, os quais contribuem para o desenvolvimento de fenótipos de multiresistência às classes de antibióticos clinicamente mais relevantes. Dado que a terapêutica seleccionada pode actuar como indutora e originar eventos mutacionais que promovem a hiperexpressão das bombas de efluxo, o tratamento destas infecções constitui um grande desafio terapêutico e impõe um conhecimento actualizado desta temática. Esta revisão foi assim desenvolvida com o intuito de rever a contribuição da hiperexpressão dos sistemas de bombas de efluxo em P.aeruginosa, na multirresistência aos antibióticos. Pretendeu-se também avaliar a possibilidade da utilização destes sistemas como alvos terapêuticos de modo a restabelecer a susceptibilidade aos antibióticos disponíveis.

Aluminum and Sulphate Removal by a Highly Al-Resistant Dissimilatory Sulphate-Reducing Bacteria Community

A highly Al-resistant dissimilatory sulphatereducing bacteria community was isolated from sludge of the wetland of Urgeiriça mine (community W). This community showed excellent sulphate removal at the presence of Al3+. After 27 days of incubation, 73,86 and 81% of sulphate was removed in the presence of 0.48, 0.90 and 1.30 mM of Al3+, respectively. Moreover,Al3+ was simultaneously removed: 55,85 and 78% of metal was removed in the presence of 0.48, 0.90 and 1.30 mM of Al3+, respectively. The dissociation of aluminiumlactate soluble complexes due to lactate consumption by dissimilatory sulphate-reducing bacteria can be responsible for aluminum removal, which probably precipitates as insoluble aluminium hydroxide. Phylogenetic analysis of 16S rRNA gene showed that this community was mainly composed by bacteria closely related to Desulfovibrio desulfuricans. However, bacteria affiliated to Proteus and Ralstonia were also present in the community.

Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema

Diabetic macular oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. Corticosteroid drugs have been demonstrated to inhibit the expression of both the vascular endothelial growth factor (VEGF) gene and other anti-inflammatory mediators, such as prostaglandins. Triamcinolone, fluocinolone and dexamethasone are the main steroids that have been studied for the treatment of macular oedema. Over the last few years, several studies have suggested an important role for dexamethasone in the management of DMO. The dexamethasone intravitreal implant (DEX implant) (Ozurdex®; Allergan, Inc., Irvine, CA) is a novel approach approved by the US Food and Drug Administration (FDA) and by the EU for the intravitreal treatment of macular oedema after branch or central retinal vein occlusion, and for the treatment of non-infectious uveitis affecting the posterior segment of the eye. We reviewed manuscripts that had investigated the pharmacokinetics, efficacy and safety of the DEX implant regarding DMO treatment.